Japanese startup test kit shows promise in early cancer detection
KYODO NEWS - 3 hours ago - 10:02 | All, Japan
A urine-based cancer risk screening kit developed by a Japanese startup is showing promise in detecting cancer at the earliest stage using non-invasive means.
The test kit from Craif Inc., a spin-off from Nagoya University founded in 2018, can also be used to assess simultaneously whether a person is at risk from any of up to seven types of cancer.
The product, which does not require a blood test, was able to detect changes in pre-malignant cells among residents of Hokkaido towns in northern Japan to whom the company distributed 100 sets of the "miSignal" test kit free of charge in the year through March 2025.
"We were able to detect and treat cancer that was difficult to find by X-ray," said Tatsuya Kato, a professor at the Hokkaido University Hospital, adding the kits would be vital in places such as Hokkaido, where medical resources are sparse.
The kit can be used to detect microRNA, a biomarker known for its link to early cancer biology, in a small amount of urine and help screen the risks of cancer in the lungs, colon and pancreas, among others.
Results of the survey using the test kits were announced at an annual meeting of the Japanese Association for Chest Surgery in May.
Among those aged 60 or older who had not taken a lung cancer test for five years or more, a tumor was detected in the lungs of a woman in her 60s that led to a detailed examination and successful surgery. The tumor was diagnosed as a "Stage 0" adenocarcinoma in situ.
Precancerous cells in the colon and pancreas were also detected among six people in the survey, according to the company.
In Japan, it is estimated that one in two people would develop cancer in their lifetime, while one in four men and one in six women will die from the disease, according to statistics of the National Cancer Center Japan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
2 hours ago
Pills or Perseverance: How Japan and Other Nations Tackle Headaches
The Japanese pharmaceutical company SSP conducted a survey on headaches resulting from changes in weather or atmospheric pressure, targeting 500 respondents in each of the following five countries: Britain, China, Germany, Japan, and the United States. The survey found that 70.8% of the respondents in Japan 'often' or 'occasionally' experience such headaches, with similar percentages for the other countries. When asked whether headaches should be endured to some extent, 78.2% of respondents in Germany either 'strongly agreed' or 'somewhat agreed,' which was the highest level among the five countries. Japan had the lowest level of agreement, at 59.8%. However, 77.2% of the respondents in Japan said that they do in fact tend to endure their headaches. This suggests a significant gap between the attitude towards headaches and actual behavior. When asked how long they wait before taking medicine after noticing a headache, more than half of respondents in the United States said 30 minutes or less, which was shorter in general than for those in other countries. Meanwhile, there is a striking tendency in Japan for people to endure headaches without the help of medicine. The survey results show that 17.8% of the Japanese respondents take no medicine at all for a headache, which was the highest percentage among the five countries. (Translated from Japanese. Banner photo © Pixta.)
Kyodo News
8 hours ago
- Kyodo News
Japanese startup test kit shows promise in early cancer detection
KYODO NEWS - 5 hours ago - 13:02 | All, Japan A urine-based cancer risk screening kit developed by a Japanese startup is showing promise in detecting cancer at the earliest stage using non-invasive means. The test kit from Craif Inc., a spin-off from Nagoya University founded in 2018, can also be used to assess simultaneously whether a person is at risk from any of up to seven types of cancer. The product, which does not require a blood test, was able to detect changes in pre-malignant cells among residents of Hokkaido towns in northern Japan to whom the company distributed 100 sets of the "miSignal" test kit free of charge in the year through March 2025. "We were able to detect and treat cancer that was difficult to find by X-ray," said Tatsuya Kato, a professor at the Hokkaido University Hospital, adding the kits would be vital in places such as Hokkaido, where medical resources are sparse. The kit can be used to detect microRNA, a biomarker known for its link to early cancer biology, in a small amount of urine and help screen the risks of cancer in the lungs, colon and pancreas, among others. Results of the survey using the test kits were announced at an annual meeting of the Japanese Association for Chest Surgery in May. Among those aged 60 or older who had not taken a lung cancer test for five years or more, a tumor was detected in the lungs of a woman in her 60s that led to a detailed examination and successful surgery. The tumor was diagnosed as a "Stage 0" adenocarcinoma in situ. Precancerous cells in the colon and pancreas were also detected among six people in the survey, according to the company. In Japan, it is estimated that one in two people would develop cancer in their lifetime, while one in four men and one in six women will die from the disease, according to statistics of the National Cancer Center Japan.
Kyodo News
13 hours ago
- Kyodo News
Japanese startup test kit shows promise in early cancer detection
KYODO NEWS - 3 hours ago - 10:02 | All, Japan A urine-based cancer risk screening kit developed by a Japanese startup is showing promise in detecting cancer at the earliest stage using non-invasive means. The test kit from Craif Inc., a spin-off from Nagoya University founded in 2018, can also be used to assess simultaneously whether a person is at risk from any of up to seven types of cancer. The product, which does not require a blood test, was able to detect changes in pre-malignant cells among residents of Hokkaido towns in northern Japan to whom the company distributed 100 sets of the "miSignal" test kit free of charge in the year through March 2025. "We were able to detect and treat cancer that was difficult to find by X-ray," said Tatsuya Kato, a professor at the Hokkaido University Hospital, adding the kits would be vital in places such as Hokkaido, where medical resources are sparse. The kit can be used to detect microRNA, a biomarker known for its link to early cancer biology, in a small amount of urine and help screen the risks of cancer in the lungs, colon and pancreas, among others. Results of the survey using the test kits were announced at an annual meeting of the Japanese Association for Chest Surgery in May. Among those aged 60 or older who had not taken a lung cancer test for five years or more, a tumor was detected in the lungs of a woman in her 60s that led to a detailed examination and successful surgery. The tumor was diagnosed as a "Stage 0" adenocarcinoma in situ. Precancerous cells in the colon and pancreas were also detected among six people in the survey, according to the company. In Japan, it is estimated that one in two people would develop cancer in their lifetime, while one in four men and one in six women will die from the disease, according to statistics of the National Cancer Center Japan.
